{"entity":{"id":"nct06499285","kind":"trial","name":"A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular B","aka":[],"tldr":"A phase 3 trial of Elritercept run by Takeda, now recruiting.","summary":"A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions is a phase 3 interventional study registered as NCT06499285 by Takeda, with 225 participants planned, started 2025-05-06. Conditions listed: Myelodysplastic Syndromes. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06499285","url":"https://clinicaltrials.gov/study/NCT06499285"}],"tags":["ctgov-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["elritercept"],"companies":["takeda"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06499285","phase":"3","setting":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants With Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) (RENEW)","sponsor":"Takeda","enrolled":225,"outcomes":[]},"route":"/trials/nct06499285/","neighbours":{"drug":[{"id":"elritercept","kind":"drug","name":"Elritercept","route":"/drugs/elritercept/"}],"company":[{"id":"takeda","kind":"company","name":"Takeda","route":"/companies/takeda/"}]}}